Immunocore has a sip with USD140m private placement
Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.
ADVERTISEMENT
About Georg Kääb
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 91 entries already.
Entries by Georg Kääb
Worldview national ranking of health biotech sectors
A current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri)
European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Spatial Biology Company Navinci (Olink) closes EUR9m Series A
Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration, a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.
Novo Nordisk snatches Dicerna
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Delivering on Europe´s Green Deal – EFIB 2021 in Vienna
Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.
Truffle’s BioMedTech fund filled with €250m
Paris-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach.
Boehringer and Zealand to advance obesity drug
German pharma company Boehringer Ingelheim said the phase II trial for candidate drug BI456906 is expected to be initiated in late 2019 triggering a €20m milestone payment to Zealand Pharma A/S.
Investors pool €27m for new Proteomics tech
UK-based biotech startup Fluidic Analytics has raised €27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners.
Global Bioenergies delivers first batch of cosmetics ingredient
French green chemistry specialist Global Bioenergies announced the delivery of a first batch of sustainable cosmetic ingredients to cosmetics heavyweight L’Oréal. It was produced as part of the ISOPROD project, supported by the French State’s Investissements for the Future Program.